Avadel Pharmaceuticals plc (AVDL) Analysts See $-0.30 EPS as of May, 8

April 16, 2018 - By Sonya McDaniel

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is anticipated to announce earnings on May, 8., RTT reports. The EPS diference is $0.56 or 215.38 % down from last years number. Previous year: $0.26; Analysts forcast: $-0.30. Analysts at Wall Street see Avadel Pharmaceuticals plc’s 7.14 % negative EPS growth compared to $-0.28 EPS for last quarter. The stock decreased 1.65% or $0.12 during the last trading session, reaching $7.15.Avadel Pharmaceuticals plc has volume of 162,893 shares. Since April 17, 2017 AVDL has declined 26.36% and is downtrending. The stock underperformed the S&P500 by 37.91%.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland.The company has $271.36 million market cap. The company's owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs.The P/E ratio is 4.39. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.